EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
Fiche publication
Date publication
décembre 2011
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Wynes MW, Kato Y, Tran C, Asuncion BR, Zhao JM, Gustavson M, Ranger-Moore J, Gaire F, Matsubayashi J, Nagao T, Yoshida K, Ohira T, Ikeda N, Hirsch FR
Lien Pubmed
Résumé
Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC).
Mots clés
Adult, Aged, Aged, 80 and over, Binding Sites, Carcinoma, Non-Small-Cell Lung, drug therapy, ErbB Receptors, antagonists & inhibitors, Female, Fluorescent Antibody Technique, methods, Gefitinib, Humans, Image Processing, Computer-Assisted, methods, Immunohistochemistry, methods, Kaplan-Meier Estimate, Lung Neoplasms, drug therapy, Male, Middle Aged, Multivariate Analysis, Mutation, Outcome Assessment (Health Care), statistics & numerical data, Prognosis, Proportional Hazards Models, Protein Kinase Inhibitors, therapeutic use, Quinazolines, therapeutic use, Tissue Array Analysis
Référence
Clin. Cancer Res.. 2011 Dec 15;17(24):7796-807